Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
Sponsor: Alexion Pharmaceuticals, Inc.
Summary
The primary purpose of this study is to assess the safety and tolerability of single ascending doses of ALXN2030 in healthy participants.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2022-08-16
Completion Date
2026-10-14
Last Updated
2026-04-09
Healthy Volunteers
Yes
Conditions
Interventions
ALXN2030
ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
Placebo
Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
Locations (1)
Research Site
Harrow, United Kingdom